Cainzos-Achirica et al evaluated the prognostic implications of IL-6 levels on hard coronary heart disease (CHD) events, stroke, hard atherosclerotic CVD, and incident heart failure (HF) in patients without clinical CVD using the MESA (Multi-Ethnic Study of Atherosclerosis); however, the analysis was focused on assessing differences between users and nonusers of statins and did not assess the impact of race and ethnicity on clinical outcomes.11 The gene discussed is IL6; the disease is coronary artery disorder.